Amplia Therapeutics (ASX:ATX) Debt-to-Asset : 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATX Amplia Therapeutics Ltd ASX:ATX
28 GF Score
Price A$0.15
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Debt-to-Asset?

Amplia Therapeutics ASX:ATX 28 Debt-to-Asset is 0.01 as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was A$0.09 Mil. Amplia Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was A$0.25 Mil. Amplia Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was A$41.44 Mil. Amplia Therapeutics's debt to asset for the quarter that ended in Mar. 2026 was 0.01.

Amplia Therapeutics  (ASX:ATX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Amplia Therapeutics Debt-to-Asset Related Terms

Amplia Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Debt-to-Asset Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.12 0.11 0.00 0.01

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.00 0.00 0.01 0.01

ASX:ATX vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, Amplia Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Debt-to-Asset falls into.


ASX:ATX
28GF Score
Amplia Therapeutics Ltd ASX:ATX
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Amplia Therapeutics's Debt-to-Asset for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.089 + 0.252) / 41.441
=0.01

Amplia Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.089 + 0.252) / 41.441
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
Amplia Therapeutics (ASX:ATX) has a Debt-to-Asset of 0.01 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Debt-to-Asset too high?
Amplia Therapeutics' current Debt-to-Asset is 0.01. Overall, Amplia Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Debt-to-Asset compare to VRTX and REGN?
Amplia Therapeutics' Debt-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. Amplia Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Debt-to-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
28GF Score

Get the complete analysis for ASX:ATX

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price